INSM - Why Lung Disease Focused Stock Insmed Is Trading Higher Today? | Benzinga
Insmed Incorporated (NASDAQ: INSM) shares are trading higher after the company released topline results from its Phase 3 ARISE study of ARIKAYCE in patients with newly diagnosed or recurrent nontuberculous mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC) who had not started antibiotics.
The study met its primary objective of demonstrating that the Quality of Life – Bronchiectasis (QOL-B) respiratory domain works effectively as a patient-reported outcome (PRO) instrument in patients with MAC lung disease.
Insmed plans to propose to the ...